EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elevated gonadotropin levels are associated with increased biomarker risk of Alzheimer's disease in midlife women

Matilde Nerattini, Federica Rubino, Steven Jett, Caroline Andy, Camila Boneu, Camila Zarate, Caroline Carlton, Susan Loeb-Zeitlin, Yelena Havryliuk, Silky Pahlajani, Schantel Williams, Valentina Berti und 5 weitere

Frontiers in Dementia · 23.11.2023 · 2

DOI: 10.3389/frdem.2023.1303256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Dementia, online erschienen am 23.11.2023. Verfasst von Matilde Nerattini und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Weill Cornell Medicine, New York, NY, United States. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NCATS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In preclinical studies, menopausal elevations in pituitary gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH), trigger Alzheimer's disease (AD) pathology and synaptic loss in female animals. Herein, we took a translational approach to test whether gonadotropin elevations are linked to AD pathophysiology in women.

Methods

We examined 191 women ages 40–65 years, carrying risk factors for late-onset AD, including 45 premenopausal, 67 perimenopausal, and 79 postmenopausal participants with clinical, laboratory, cognitive exams, and volumetric MRI scans. Half of the cohort completed 11 C-Pittsburgh Compound B (PiB) amyloid-β (Aβ) PET scans. Associations between serum FSH, LH and biomarkers were examined using voxel-based analysis, overall and stratified by menopause status. Associations with region-of-interest (ROI) hippocampal volume, plasma estradiol levels, APOE-4 status, and cognition were assessed in sensitivity analyses.

Results

FSH levels were positively associated with Aβ load in frontal cortex (multivariable adjusted P ≤ 0.05, corrected for family wise type error, FWE), an effect that was driven by the postmenopausal group (multivariable adjusted P FWE ≤ 0.044). LH levels were also associated with Aβ load in frontal cortex, which did not survive multivariable adjustment. FSH and LH were negatively associated with gray matter volume (GMV) in frontal cortex, overall and in each menopausal group (multivariable adjusted P FWE ≤ 0.040), and FSH was marginally associated with ROI hippocampal volume (multivariable adjusted P = 0.058). Associations were independent of age, clinical confounders, menopause type, hormone therapy status, history of depression, APOE-4 status, and regional effects of estradiol. There were no significant associations with cognitive scores.

Discussion

Increasing serum gonadotropin levels, especially FSH, are associated with higher Aβ load and lower GMV in some AD-vulnerable regions of midlife women at risk for AD. These findings are consistent with preclinical work and provide exploratory hormonal targets for precision medicine strategies for AD risk reduction.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseaseMagnetic Resonance Imaging (MRI)gonadotropin (FSH and LH)menopauseneuroimagingpositron emission tomography (PET)women

Autor:innen und Institutionen

  • Department of Neurology, Weill Cornell Medicine, New York, NY, United States.
  • Department of Experimental and Clinical Biomedical Sciences, Nuclear Medicine Unit, University of Florence, Florence, Italy.
  • Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, United States.
  • Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, United States.
  • Department of Radiology, Weill Cornell Medicine, New York, NY, United States.
  • Department of Neurology and Pharmacology, University of Arizona, Tucson, AZ, United States.

Förderung

  • NIA NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health

Zitieren

APA

Nerattini, M., Rubino, F., Jett, S., Andy, C., Boneu, C., Zarate, C., Carlton, C., Loeb-Zeitlin, S., Havryliuk, Y., Pahlajani, S., Williams, S., Berti, V., Christos, P., Fink, M., Dyke, J. P., Brinton, R. D., & Mosconi, L. (2023). Elevated gonadotropin levels are associated with increased biomarker risk of Alzheimer's disease in midlife women. Frontiers in Dementia, 2. https://doi.org/10.3389/frdem.2023.1303256

Vancouver

Nerattini M, Rubino F, Jett S, Andy C, Boneu C, Zarate C, et al. Elevated gonadotropin levels are associated with increased biomarker risk of Alzheimer's disease in midlife women. Frontiers in Dementia. 2023;2. doi:10.3389/frdem.2023.1303256

BibTeX
@article{Nerattini2023,
  author = {Nerattini, Matilde and Rubino, Federica and Jett, Steven and Andy, Caroline and Boneu, Camila and Zarate, Camila and Carlton, Caroline and Loeb-Zeitlin, Susan and Havryliuk, Yelena and Pahlajani, Silky and Williams, Schantel and Berti, Valentina and Christos, Paul and Fink, Matthew and Dyke, Jonathan P and Brinton, Roberta Diaz and Mosconi, Lisa},
  title = {Elevated gonadotropin levels are associated with increased biomarker risk of Alzheimer's disease in midlife women},
  journal = {Frontiers in Dementia},
  year = {2023},
  volume = {2},
  doi = {10.3389/frdem.2023.1303256}
}
Kostenlos starten →